Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 2/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.40 |
| ▸ | MAP2K6 | P52564 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.40 |
| ▸ | NEK10 | Q6ZWH5 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1179339 | 0.90 | GPR3 (0.67) | GPR3LCKMAP2K3MAP2K6BTK | |
| Benzonaphthyridine SCHEMBL29600756 | 0.73 | GPR3 (1.00) | GPR3LCKMAP2K3MAP2K6BTK | |
| Benzonaphthyridine SCHEMBL51197 | 0.73 | GPR3 (1.00) | GPR3LCKMAP2K3MAP2K6BTK | |
| Benzonaphthyridine SCHEMBL30897319 | 0.73 | GPR3 (1.00) | GPR3LCKMAP2K3MAP2K6BTK | |
| Triphenylene SCHEMBL1756536 | 0.73 | CA2 (0.50) | ALOX15TSHRCA12 | |
| SCHEMBL4485428 | 0.68 | GPR3 (0.87) | GPR3LCKMAP2K3MAP2K6BTK | |
| SCHEMBL4070170 | 0.68 | GPR3 (0.46) | GPR3LCKMAP2K3MAP2K6BTK | |
| SCHEMBL3630295 | 0.67 | ALDH1A1 (0.43) | GPR3LCKMAP2K3MAP2K6BTK | |
| SCHEMBL10742424 | 0.64 | GPR3 (0.41) | GPR3LCKMAP2K3MAP2K6BTK | |
| Quinoxaline SCHEMBL10841319 | 0.63 | ALDH1A1 (0.44) | KMT2AMEN1SMN1; SMN2ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384935-B2 | Phosphate prodrugs of a farnesyl dibenzodiazepinone, processes for their production and their use as pharmaceuticals | THALLION PHARMACEUTICALS, INC. (CA) | 2008-06-10 | — | — | US | disclosed |
| WO-2007038512-A2 | PHOSPHATE PRODRUGS OF A FARNESYL DIBENZODIAZEPINONE, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | THALLION PHARMACEUTICALS INC. (CA) | 2007-04-05 | — | — | WO | disclosed |
| US-20070078112-A1 | Phosphate prodrugs of a farnesyl dibenzodiazepinone, processes for their production and their use as pharmaceuticals | ECOPIA BIOSCIENCES INC. | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078112-A1 | Phosphate prodrugs of a farnesyl dibenzodiazepinone, processes for their production and their use as pharmaceuticals | FDPS, GGPS1, FNTA | GPR3 1748/4885LCK 3827/4885MAP2K3 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.